Supplementary Information

Barium titanate nanoparticles sensitise treatment-resistant breast cancer cells to the antitumor action of tumour-treating fields

Yi Na Yoon[a,b,§], Dae-Sik Lee[c,§], Hyung Ju Park[c,*], and Jae-Sung Kim[a,b,*]

[a]Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, Seoul 01812, South Korea

[b]Radiological and Medico-Oncological Sciences, University of Science and Technology, Daejeon 34113, South Korea

[c]Electronics and Telecommunications Research Institute, Daejeon 34129, South Korea

[§]Y.N.Y. and D.-S.L. contributed equally to the work

*__Corresponding author__: Jae-Sung Kim, Division of Radiation Biomedical Research, Korea Institute of Radiological and Medical Sciences, 75, Nowon-ro, Nowon-Ku, Seoul 01812, South Korea. Phone: +82-2-970-1669, Fax: +82-2-970-2417, E-mail: jaesung@kirams.re.kr or Hyung Ju Park, Welfare & Medical ICT Research Department, Electronics and Telecommunications Research Institute (ETRI), 218 Gajeong-ro, Yuseong-gu, Daejeon, 34129, South Korea. Phone: +82-42-860-1474, Fax: +82-42-860-6594, E-mail: park77@etri.re.kr

Supplementary Figure

Supplementary figure S1. Cytocompatibility of BTNPs in breast cancer cells. (a-d) Cell proliferation in MCF-7 and BT549 cells upon BTNP treatment with or without FBS-coating. Data represent mean ± standard deviation of three independent experiments; $**P < 0.01$, and $*P < 0.05$. N.S. not significant.



Supplementary figure S2. Cytoplasmic accumulation of BTNPs with inhibitors in MCF-7 cells in response to TTFields. (a) Schematic summary of the experiment. (b) Representative images showing cytosolic localisation of BTNPs in MCF-7 cells treated with TTFields or TTFields plus BTNPs without or with cytochalasin D and amiloride. Data is representative of three independent experiments.



Supplementary figure S3. XRD spectral changes of $BaTiO_3$ nanoparticles. (a) Schematic summary of the experiment.



Supplementary figure S4. Original blots used for Figure 6 (b).